Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure.

Dorsheimer L, Assmus B, Rasper T, Ortmann CA, Ecke A, Abou-El-Ardat K, Schmid T, Brüne B, Wagner S, Serve H, Hoffmann J, Seeger F, Dimmeler S, Zeiher AM, Rieger MA. · 2019

Read Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure. by Dorsheimer L, Assmus B, Rasper T, Ortmann CA, Ecke A, Abou-El-Ardat K, Schmid T, Brüne B, Wagner S, Serve H, Hoffmann J, Seeger F, Dimmeler S, Zeiher AM, Rieger MA. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6439691.txt.

Introduction

Dorsheimer and co-authors examine clonal hematopoiesis, the age-linked expansion of blood cell clones carrying mutations, in 200 patients with chronic ischemic heart failure. Such clones, especially in the genes DNMT3A and TET2, were already tied to coronary disease and inflammation. Their meaning for patients who already have heart failure was untested.

CHIP proved common in the cohort, and carriers matched non-carriers on standard clinical measures apart from age. During follow-up, 37 percent of carriers died against 24 percent of non-carriers, and DNMT3A or TET2 mutations in particular predicted more deaths and repeat hospitalizations. The authors present clonal hematopoiesis as a new, potentially targetable risk factor in heart failure.

Catalog record

CREATORDorsheimer L, Assmus B, Rasper T, Ortmann CA, Ecke A, Abou-El-Ardat K, Schmid T, Brüne B, Wagner S, Serve H, Hoffmann J, Seeger F, Dimmeler S, Zeiher AM, Rieger MA.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE33 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6439691

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Association of Mutations Contributing to Clonal Hematopoiesis With Prognosis in Chronic Ischemic Heart Failure By Lena Dorsheimer, Birgit Assmus, Tina Rasper, Christina A. Ortmann, Andreas Ecke, Khalil Abou-El-Ardat, Tobias Schmid, Bernhard Brüne, Sebastian Wagner, Hubert Serve, Jedrzej Hoffmann, Florian Seeger Published in: JAMA Cardiology DOI: 10.1001/jamacardio.2018.3965 ABSTRACT Key Points Question What is the clinical significance of clonal hematopoiesis of indeterminate potential (CHIP) for chronic heart failure (CHF) owing to ischemic origin? Findings In this cohort study, CHIP had a high prevalence in 200 investigated patients with CHF. While no clinical baseline characteristics associated with CHF were different between CHIP carriers and non-CHIP carriers, except for the mean age, harboring mutations in the most prevalent driver genes associated with CHIP, namely DNMT3A and TET2, was associated with a significant and profound increase in death and rehospitalization for heart failure. Meaning Clonal hematopoiesis of indeterminate potential is presented as a newly identified risk factor for impaired long-term survival and increased disease progression in patients with CHF that may be well targetable as a valuable approach to precision medicine in patients with CHF carrying specific mutations encoding for clonal hematopoiesis. INTRODUCTION Clonal hematopoiesis of indeterminate potential (CHIP) is defined as the presence of an expanded somatic blood cell clone in persons without other hematological abnormalities.1,2,3 The presence of CHIP was shown to increase with age and is significantly associated with the risk for coronary heart disease.2,4 The most commonly mutated genes in CHIP are the DNA methyltransferase DNMT3A and the DNA demethylase TET2, which both epigenetically control gene expression. Functionally, these 2 predominant CHIP driver genes are important regulators of inflammation by augmenting monocyte adhesion and stimulated macrophage activity.5,6 Accordingly, loss of TET2 function in hematopoietic cells accelerates atherosclerosis and promotes inflammasome activation in mice,4,7 whereas loss of DNMT3A experimentally altered myeloid cell function and promoted upregulation of chemokines.8,9 Aging is the major risk factor for heart failure,10 and inflammation importantly contributes to the progression of ischemic heart failure.11 However, to our knowledge, there are no data assessing the incidence and potential prognostic significance of the presence of CHIP in patients with chronic heart failure (CHF) owing to ischemic origin. Therefore, we used targeted amplicon sequencing to detect the presence of CHIP in bone marrow–derived mononuclear cells (BMC) and associated such presence with long-term prognosis in patients with chronic ischemic heart failure. METHODS Study Cohort Clinical data and biological specimens (BMC) were collected from a total of 200 patients with CHF and participating in different trials examining the effects of intracoronary administration of autologous BMCs between June 2005 and July 2017 at the University Hospital of the Goethe University, Frankfurt/Main, Germany. All patients provided written informed consent for 1 of the following registered clinical trials: Transplantation of Progenitor Cells and Recovery of Left Ventricular Function in Patients with Chronic Ischemic Heart Disease (TOPCARE-CHD; Crossover or Registry; n = 134; NCT00289822 or NCT0096236412,13), Cellwave (n = 55; NCT0032698914) or Repetitive Progenitor Cell Therapy in Advanced Chronic Heart Failure (REPEAT; n = 11; NCT0169304213). The selection of patients from the individual parent trials is illustrated in the eFigure in the Supplement. In addition to the clinical trials, patients provided additional informed consent for genetic testing of bone marrow samples. The ethics review board of the Goethe University in Frankfurt, Germany, approved the protocols. The study complies with the Declaration of Helsinki. Patients were eligible for inclusion into the study if they had stable CHF symptoms New York Heart Association (NYHA) classification of at least II, had a previous successfully revascularized myocardial infarction at least 3 months before bone marrow aspiration, and had a well-demarcated region of left ventricular dysfunction on echocardiography. Exclusion criteria were the presence of acutely decompensated heart failure with NYHA class IV, an acute ischemic event within 3 months prior to inclusion, a history of severe chronic diseases, documented cancer within the preceding 5 years, or unwillingness to participate. Clinical data, medication, and laboratory data were prospectively collected. Follow-up visits were scheduled at 3 to 4 months after cell application and at 12 months after cell application and were performed by physicians, whereas follow-up telephone calls were performed by study nurses at 18, 24, 36, and 48 months. The Seattle Heart Failure Model (SHFM) score was calculated by including age, sex, etiology of cardiomyopathy (ischemic origin), heart rate, systolic blood pressure, ejection fraction, medication (angiotensin-converting enzyme inhibitor, angiotensin receptor blocker, aldosterone blocker, β-blocker, statins, diuretic type and daily dose, and allopurinol), and laboratory values (serum sodium, total cholesterol, hemoglobin, percent lymphocytes, and uric acid). In addition, the presence of any implantable device (pacemaker, implantable cardioverter-defibrillator, or cardiac resynchronization therapy) is included into the calculation of the SHFM Score. N-terminal pro b-type natriuretic peptide (NT-proBNP) serum levels were measured at the time of bone marrow harvest. Mortality and mode of death were adjudicated by means of reviewing medical records by the study physicians. Mode of death was classified as sudden death (unexpected death in a clinically stable patient, typically within 1 hour of symptom onset, from documented or presumed cardiac arrhythmia and without a clear noncardiovascular cause), pump failure (progressively reduced cardiac output and failure of organ perfusion), noncardiac death, or not classifiable. Missing data on survival were obtained by contacting the federal registration offices. Rehospitalization for heart failure was defined as an at least 24 hours’ hospital stay for heart failure symptoms with documented change in heart failure–directed medication. Physicians assessing heart failure admissions were unaware of the mutation status of the patients. Sample Preparation for Next-Generation Sequencing Bone marrow aspirate (50 mL) was obtained from the iliac crest with local anesthesia. Bone marrow–derived mononuclear cells were isolated by Ficoll density-gradient centrifugation, as previously reported.12,15 DNA was isolated with QIAamp DNA Mini Kit (Qiagen) from deep-frozen samples of BMC and peripheral blood. The concentration of the extracted genomic DNA was determined using the Qubit dsDNA HS Assay Kit (Life Technologies) on a Qubit Fluorometer (Life Technologies). A custom panel based on the Illumina TruSeq Custom Amplicon Low Input assay was designed to assess the presence of CHIP in the patients. The panel includes 594 amplicons in 56 genes (eTable 1 in the Supplement) commonly mutated in CHIP and myeloid malignancies. To allow improved identification of low allele frequency variants, a dual-strand approach was used. In addition, 6-bp unique molecular identifiers (UMIs) were included in the target specific primers. Target enrichment was performed from 40-ng genomic DNA according to the instructions of the TruSeq Custom Amplicon Low Input Kit (Illumina). The hybridization of the oligo pool to the target regions, the extension from the upstream oligo, and the following ligation to the 5′ end of the downstream oligo was performed on a T100 Thermal Cycler (Bio-Rad Laboratories). Amplification of the ligation products and addition of the Illumina i7 and i5 adapter sequences was performed on a T100 Thermal Cycler (Bio-Rad Laboratories). After purification, library quality and size distribution were assessed on a Bioanalyzer 2100 (Agilent Technologies) using the DNA 1000 Kit. Bead-based library normalization was performed before pooling of the individual libraries. High-Throughput Sequencing Before sequencing, the pooled libraries were diluted and denatured according to the NextSeq System Denature and Dilute Libraries Guide (Illumina) and 1% PhiX DNA was added. The pooled libraries

Read the complete text